Article
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.
Nature communications - 14 May 2020
Vander Velde Robert, Yoon Nara, Marusyk Viktoriya, Durmaz Arda, Dhawan Andrew, Miroshnychenko Daria, Lozano-Peral Diego, Desai Bina, Balynska Olena, Poleszhuk Jan, Kenian Liu, Teng Mingxiang, Abazeed Mohamed, Mian Omar, Tan Aik Choon, Haura Eric, Scott Jacob, Marusyk Andriy
Abstract excerpt
Despite high initial efficacy, targeted therapies eventually fail in advanced cancers, as tumors develop resistance and relapse. In contrast to the substantial body of research on the molecular mechanisms of resistance, understanding of how resistance evolves remains limited. Using an experimental model of ALK positive NSCLC, we explored the evolution of resistance to different clinical ALK inhibitors. We found...
Topics
Join the communities discussing this publication.